首页|There is nothing exempt from the peril of mutation - The Omicron spike
There is nothing exempt from the peril of mutation - The Omicron spike
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
The 2019 corona virus disease (COVID-19) has caused a global chaos， where a novel Omicron variant has challenged the healthcare system， followed by which it has been referred to as a variant of concern (VOC) by the World Health Organization (WHO)， owing to its alarming transmission and infectivity rate。 The large number of mutations in the receptor binding domain (RBD) of the spike protein is responsible for strengthening of the spike-angiotensin-converting enzyme 2 (ACE2) interaction， thereby explaining the elevated threat。 This is supplemented by enhanced resistance of the variant towards pre-existing antibodies approved for the COVID-19 therapy。 The manuscript brings into light failure of existing therapies to provide the desired effect， however simultaneously discussing the novel possibilities on the verge of establishing suitable treatment portfolio。 The authors entail the risks associated with omicron resistance against antibodies and vaccine ineffectiveness on one side， and novel approaches and targets - kinase inhibitors， viral protease inhibitors， phytoconstituents， entry pathways - on the other。 The manuscript aims to provide a holistic picture about the Omicron variant， by providing comprehensive discussions related to multiple aspects of the mutated spike variant， which might aid the global researchers and healthcare experts in finding an optimised solution to this pandemic。
Corona virusOmicronVariant of concernReceptor binding domainSpikeACE2
Tapan Behl、Ishnoor Kaur、Aayush Sehgal、Sukhbir Singh、Neelam Sharma、Md Khalid Anwer、Hafiz A. Makeen、Mohammed Albratty、Hassan A. Alhazmi、Saurabh Bhatia、Simona Bungau
展开 >
Chitkara College of Pharmacy, Chitkara University, Punjab, India
NSTL
